The role of new interferons in the era of STAT-C
- 1 September 2009
- journal article
- Published by Springer Nature in Nature Reviews Gastroenterology & Hepatology
- Vol. 6 (9) , 509-511
- https://doi.org/10.1038/nrgastro.2009.141
Abstract
More than 50% of patients infected with HCV genotype 1 fail respond to standard treatment with peginterferon plus ribavirin. Potent treatment strategies are urgently needed to improve outcomes for such patients. Novel interferons and specifically targeted antiviral therapy for HCV (STAT-C) represent promising strategies.Keywords
This publication has 11 references indexed in Scilit:
- Retreating chronic hepatitis C with daily interferon alfacon‐1/ribavirin after nonresponse to pegylated interferon/ribavirinHepatology, 2009
- Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin TherapyGastroenterology, 2009
- Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-α2bAnnals of Internal Medicine, 2009
- 1044 TELAPREVIR IN HEPATITIS C GENOTYPE-1-INFECTED PATIENTS WITH PRIOR NON-RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE TO PEGINTERFERON- ALFA-2A/B AND RIBAVIRIN THERAPY: SVR RESULTS OF THE PROVE3 STUDYJournal of Hepatology, 2009
- Hepatitis B and hepatitis C in 2009Liver International, 2009
- Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose PeginterferonNew England Journal of Medicine, 2008
- Insulin Resistance in Chronic Hepatitis C: Association With Genotypes 1 and 4, Serum HCV RNA Level, and Liver FibrosisGastroenterology, 2008
- Consensus Interferon and Ribavirin in Patients with Chronic Hepatitis C Who Were Nonresponders to Pegylated Interferon alfa-2b and RibavirinDigestive Diseases and Sciences, 2008
- High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapyJournal of Hepatology, 2007
- Peginterferon Alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment[1], [2] and [3] 1 2 3☆Gastroenterology, 2004